Skip to main content

Table 3 Pre–post differences in number of WIE, Wexner score and VAS by cause of FI (ITT)

From: Skeletal muscle-derived cell implantation for the treatment of sphincter-related faecal incontinence

  Muscle damage
(N = 16)
Atrophy (N = 17) Both
(N = 6)
WIE
 V2 – V0 −6.83 (7.13) (− 10.6; – 3.0)* −6.17 (5.30) (− 8.9; – 3.4)* −10.58 (8.54) (− 19.5; – 1.6)*
 V3 – V0 −9.25 (9.67) (− 14.4; – 4.1)* −8.55 (7.12) (− 12.2; – 4.9)* −19.79 (15.23) (− 35.8; – 3.8)*
 V4 – V0 − 9.29 (10.08) (−14.7; – 3.9)* −8.09 (5.83) (− 11.1; – 5.1)* −23.33 (13.14) (− 19.5; – 1.6)*
Wexner score
 V2 – V0 −13.44 (5.23) (− 16.2; – 10.7)* −16.82 (3.81) (− 18.8; – 14.9)* − 15.33 (3.50) (− 19.0; – 11.7)*
 V3 – V0 −14.25 (4.99) (− 16.2; – 10.7)* −18.29 (2.39) (− 19.5; – 17.1)* −14.50 (4.97) (− 19.7; – 9.3)*
 V4 – V0 − 14.94 (4.42) (− 16.9; – 11.6)* −17.71 (1.99) (− 18.7; – 16.7)* −17.67 (3.14) (− 21.0; – 14.4)*
VAS
 V2 – V0 −2.79 (2.11) (− 3.9; – 1.7)* −3.07 (2.40) (− 4.4; – 1.7)* −2.37 (1.72) (− 4.2; – 0.6)*
 V3 – V0 −3.65 (− 2.60) (− 5.0; – 2.3)* −4.23 (2.41) (− 5.6; – 2.8)* −4.10 (1.47) (− 5.9; – 2.3)*
 V4 – V0 −3.71 (2.84) (− 5.2; – 2.2)* − 4.45 (2.35) (− 5.8; – 3.1)* −5.89 (2.45) (− 9.8; – 2.0)*
  1. Data presented as mean (standard deviation) (95% confidence interval)
  2. WIE weekly incontinence episodes, VAS visual analogue scale, FI faecal incontinence, ITT intention-to-treat, N number of values, V visit, V0 implantation, V2, V3 and V4 1, 6 and 12 months post implantation
  3. *Significant change from baseline according to 95% confidence interval